List of Figures
Figure 1: Transplantation Therapeutics, US, Innovation Trends in Product Approvals, 1987–2014 6
Figure 2: Transplantation Therapeutics, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 8
Figure 3: Transplantation Therapeutics, Global, Overview of Marketed Products, 2017 22
Figure 4: Transplantation Therapeutics, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 24
Figure 5: Transplantation Therapeutics, Global, Pipeline by Stage of Development and Molecule Type, 2017 25
Figure 6: Transplantation Therapeutics, Global, Key Indications by Stage of Development and Molecule Type, 2017 26
Figure 7: Transplantation Therapeutics, Global, Pipeline by Molecular Target, 2017 27
Figure 8: Transplantation Therapeutics, Global, Key Indications by Molecular Target, 2017 28
Figure 9: Transplantation Therapeutics, Global, Distribution of Pipeline First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target, 2017 29
Figure 10: Transplantation Therapeutics, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products with a Disclosed Target by Stage of Development (%), 2017 29
Figure 11: Transplantation Therapeutics, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecular Target (%), 2017 30
Figure 12: Transplantation Therapeutics, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development, 2017 30
Figure 13: Transplantation Therapeutics, Global, Ratio of First-in-Class Products to First-in-Class Targets by Molecular Target, 2017 31
Figure 14: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 1) 31
Figure 15: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 2) 32
Figure 16: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 3) 33
Figure 17: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 4) 34
Figure 18: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 5) 35
Figure 19: Transplantation Therapeutics, Global, First-in-Class Matrix Assessment, 2017 38
Figure 20: Pharmaceutical Industry, Global, Licensing Deals by Stage of Development, 2006–2015 50
Figure 21: Pharmaceutical Industry, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status ($m), 2006–2015 51
Figure 22: Transplantation Therapeutics, Global, Licensing Deals by Region, Value and Year, 2006–2017 53
Figure 23: Transplantation Therapeutics, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 54
Figure 24: Transplantation Therapeutics, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2017 55
Figure 25: Transplantation Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006–2017 56
Figure 26: Transplantation Therapeutics, Global, Co-development Deals by Region, Value and Year, 2006–2017 58
Figure 27: Transplantation Therapeutics, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 59
Figure 28: Transplantation Therapeutics, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006–2017 60
Figure 29: Transplantation Therapeutics, Global, Co-development Deals with Disclosed Deal Values, 2006–2017 61
Figure 30: Transplantation Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 1) 62
Figure 31: Transplantation Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 2) 63